0001181431-13-005793.txt : 20130131 0001181431-13-005793.hdr.sgml : 20130131 20130131164238 ACCESSION NUMBER: 0001181431-13-005793 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20130131 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130131 DATE AS OF CHANGE: 20130131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24274 FILM NUMBER: 13563147 BUSINESS ADDRESS: STREET 1: 4370 LA JOLLA VILLAGE DR. STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 858-452-6600 MAIL ADDRESS: STREET 1: 4370 LA JOLLA VILLAGE DR. STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92122 8-K 1 rrd368276.htm MONEYSHOW PRESS RELEASE Prepared By R.R. Donnelley Financial -- Form 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  01/31/2013
 
LA JOLLA PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)
 
Commission File Number:  0-24274
 
CALIFORNIA
  
33-0361285
(State or other jurisdiction of
  
(IRS Employer
incorporation)
  
Identification No.)
 
4370 La Jolla Village Drive, Suite 400, San Diego, California 92122
(Address of principal executive offices, including zip code)
 
(858) 207-4264
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
Item 8.01.    Other Events
 
On January 31, 2013, La Jolla Pharmaceutical Company (the "Company") issued a press release. A copy of the press release is attached as Exhibit 99.1 to this Form 8-K.
 
 
Item 9.01.    Financial Statements and Exhibits
 
(d) Exhibits. The following exhibit is filed with this report on Form 8-K:
      
       Exhibit 99.1 Press Release dated January 31, 2013.
 

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
           
LA JOLLA PHARMACEUTICAL COMPANY
 
 
Date: January 31, 2013
     
By:
 
/s/    George Tidmarsh
               
George Tidmarsh
               
President and Chief Executive Officer
 
 

 

EXHIBIT INDEX
 
Exhibit No.
  
Description
EX-99.1
  
Press Release
EX-99 2 rrd368276_39177.htm PRESS RELEASE

La Jolla Pharmaceutical Company Provides Corporate Update at 2013 Orlando World MoneyShow

SAN DIEGO, CA. - (MARKETWIRE-January 31, 2013) - La Jolla Pharmaceutical Company (OTCQB: LJPC) ("La Jolla" and "Company"), a leader in the development of therapeutics that target galectin-3, announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer presented today at the 2013 Orlando World MoneyShow at the Gaylord Palms Resort and Convention Center in Kissimmee Florida. The presentation was available to attendees and via live webcast at MoneyShow.com. As part of the presentation, Dr. Tidmarsh presented detailed data from La Jolla's successful study which tested GCS-100 in a preclinical model of NASH-HCC (non-alcoholic steatohepatitis-hepatocellular carcinoma). This study was performed in collaboration with Setelic Institute in Tokyo, Japan. Also, new information about the focus and direction of La Jolla for the future was presented. A video of the webcasted presentation is available on MoneyShow.com. This information can also be found in the Company's Form 8-K filed with the SEC.

About Chronic Kidney Disease

Chronic kidney disease currently affects 14% of Americans or approximately 49 million people. The United States Renal Data System, 2012 Annual Data Report, states that in 2010, costs for CKD reached $41 billion for Medicare alone. Overall per person per year ("PPPY") costs for CKD were estimated at $22,323 for Medicare patients of age 65 and older and $13,395 for patients of age 50-64. Patients with CKD may progress to end-stage renal disease ("ESRD"). According to the National Institute of Diabetes and Digestive and Kidney Diseases as of 2008, there were 547,982 individuals in the US under treatment for ESRD and 88,630 deaths per year from ESRD.

About Chronic Liver Disease

The National Institute of Diabetes and Digestive and Kidney Diseases states that NASH affects between 7 million and 17.5 million Americans. In addition, an estimated 5.5 million Americans have chronic liver disease or cirrhosis. Together chronic liver disease and cirrhosis are currently the 12th leading cause of death, accounting for approximately 27,000 deaths annually, in the United States. Chronic Liver disease affects Americans of all ages and walks of life.

About GCS-100

GCS-100 is a complex polysaccharide that has the ability to bind to and block the effects of galectin-3. Galectin-3 is a soluble protein, over-expression of which has been implicated in a number of human diseases including cancer and chronic organ failure. The unique ability of GCS-100 to bind and sequester galectin-3 makes it an ideal candidate to prevent and treat diseases in which galectin-3 plays an important role.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company dedicated to the development of medical treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. For more information on the Company please visit http://www.ljpc.com.

Forward Looking Statement Safe Harbor

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the U.S. Securities and Exchange Commission (SEC), all of which are available free of charge on the SEC's web site http://www.sec.gov. These risks include, but are not limited to, risks relating to the development of GCS-100, the success and timing of future preclinical and clinical studies of this compound, and potential indications for which GCS-100 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.

Company Contact

George F. Tidmarsh, M.D., Ph.D.

President & Chief Executive Officer

La Jolla Pharmaceutical Company

Phone: (858) 207-4264

Email: GTidmarsh@ljpc.com

Or

Chester S. Zygmont, III

Director of Finance

La Jolla Pharmaceutical Company

Phone: (858) 207-4264

Email: czygmont@ljpc.com

 GRAPHIC 3 ljpclogo.jpg begin 644 ljpclogo.jpg M_]C_X``02D9)1@`!`0$`2`!(``#_X0"J17AI9@``34T`*@````@`!@$2``,` M```!``$```$:``4````!````5@$;``4````!````7@$H``,````!``(```$Q M``(````>````9H=I``0````!````A`````````!(`````0```$@````!061O M8F4@4&AO=&]S:&]P($-3-2!-86-I;G1O'EZ@X2% MAH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$`!\!``,!`0$!`0$!`0$````` M```!`@,$!08'"`D*"__$`+41``(!`@0$`P0'!00$``$"=P`!`@,1!`4A,082 M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3 ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C MY.7FY^CIZO+S]/7V]_CY^O_:``P#`0`"$0,1`#\`_OXH`*`"@`H`P?%/B?P_ MX)\,^(O&?BS5K+0?"WA+0]6\2^)-& MP6`PN(QN,Q-5\M/#X7"TIU\16J2Z0I4H3G)]HLY#X,^/[SXK?"GX?_$Z\\/W M/A7_`(6'X7TOQKI_AV^WBNYE2FZE.%1Q<7.*GRO>*EJE+M))KF725T<>0YC6SC)LMS:MA98 M&>9X.CCXX.H[UL-0QB26K;VW9\S>.OVQ/V<_A])=VNK_$G2]5U&R25I]*\(07 MWC&_#Q*S&V">';;4(1>N5\J&R>=;J:9XX8XGDD13]UEWAIQKF6%ECH9)7P>` MA3G6GC62XAP^ M89G6KT\-3P&30K9OB)8BM-4Z=%O`PK4*=24Y**A5K0=WJC\C_P#@X2_:KOOA M5^Q_X?\`@AX:NKW1/%'[46I-HFMY8VVJ:5\,?#Z:?JOC*VF$$S&WN-6N[S1? M#UY#YKV]UIMQKEB[R1R-G\BXBQ:HPIX+FO[>3J5G!W3H49Q]V]MJU1Q2O;GA M"K![M'Y=])KC.>1\)Y?P[AJDJ6(XHQ?^UM-J<&/B! M::O\/--BNVTG3IM/T_2?$7BG3M+\)W[/:W5HEM;Z=KEPTN^(6PFAEMY9O6>/ MP<*KP\\1"%6*C>-1\GQ13C[TK0NT]N:[UT/U.'BAP!@LWJ\*8SB/`Y;G&6PP MU"MAN$D;3_#GAK33(DFHZM?&-VV@I:V%G%=:KJMS9:38WM[; M_4\'\'9YQQG=#(\APKKXFJG5Q%>I>&$P&$@U[;&XVM:2HX>E=+:52M5E3P^' MIU<15I4I_'<=<=\.>'?#V*XCXEQBPV$H_NL-AJ=IX[,\;--T,OR[#N2EB,56 M:;WC2H4HU<5BJE'"T:U:G_,3^T!_P40^,'[3>K7MI!HI->SG%U,3.W[W$2B_9K_-GQ"\>.+_$? M%UZ-7$U,DX:]TR#PCIS`Y*.WB_5- M&UZ$8V36WAF_MV)61A7Q'C[GD\CX/6`HSY,5G^*^I73?/]2A!U</3+*)W15=E@4,2!7^9_$V(OG5:E+14\#@X1U>O//%U')>O-;3^6]]= M,OI@9I5I\?\`#^%DY>PP_#.'K4XN[@ZE?,\P=27*WO:E",K;VC=GYN_\%`KJ MT^,.N_`O]J7399-1_P"%_?`7X?Q^/[K[,\5M9?&[X0:%9?"+XH:%Y;,YCD\S MPEH7BA%8@SZ;XLTV_#S"\$S\^/QL<2\)B^:+>)P=.-1O1*OAW*C7BN[4USZ[ MQJ1?4_)?%3.*6>8OA7C.A4E5_P!9N%,HCF5;E<(0XCR&A'),ZP\5)IQG&6$P M>-_O4,PP]2+E[1R=_P#8@_X*:?M2?L*ZU86O@CQ/<^/?A")@NL_!'QSJFH7G M@R6T><274WA&1GGN?`&MN#*T6I>'T&GSW,@FUS1-DZ51;PG&[L];K=234DVF?Z9\!\>\/ M^(F0T,^X?Q#G3DU2QN#J\L<9EN,45*>%Q=--I25^:E5@Y4<13:J49RBW;ZHK ML/M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@" MO=W=M8VMS?7MQ#:6=G;S7=W=W,J0V]M;6\;37%Q<32,L<4,,2/)++(RI&BL[ M,%!-73ISJU(4J4)5*E2<:=.G"+G.KW)FB6 MYL-(&C:&[,VE--/_`*H>#_A?AO#KA##86K0IRXBS.G1QO$>+M&57ZY.FIT\K MA43E?!Y93J^PAR-PKXAXC%+E591C_C7X[>+^-\4..\;BJ=:M'AC)ZU;+N%\% M[\:2P4)I5*@/+_`'O7!SD8 M/`.,]0><]#TR>:^^Q&$O]FSV3V\]_P`_G\OS##8RRBV[J_Y_Y_=OJ?TG_P#! M#J*VU*V_:&\1%I7O5C^%^DJ6*&*.U:?XB73A"#O+R2Q1L^X;%5$\MBS2A?X@ M^E2YT\SX3P^GLUA);JVL;CXA: MS#XV^`.MW\R1VWAWX]Z=IO\`9D7AB:ZE*BTT?XT^'X;?P9>'"XLIT71A@)U)1C[/#<38>$ ML6%UIFKZ/?7>F:MIM["]O>Z?J- MC.UM>V5U!(%DBGM[B.6&2-E#*ZD,!4T<5&:4XRNGZZ-^4DFFMI)I.+O%JZ=O MSK$3KX#%U\%C:57#8S"5ZV&Q6'K0=.K0KT*DJ56E.+6DX5(N,T_ADFNU_L?_ M`()Y_MD^+_V%?VC/#?Q/TVXU"Z^'.NW%CX9^-'@^VDD>V\4>`KBZQ?Q#X3N#Y6XR%;F;HR:ABJ<5?FHWN MYM+[5)MR@]U[T=IRM^O^#7BICO#/BS!YM3K5JF3XJI2PG$&7QFW3QN6SJ)5* MD*+E&$L;@N:6(P-5N$HU4Z,JD:&)KPJ?Z)6@Z[H_BG0]&\3>'=2M-9T#Q%I6 MG:[H>KV$R7%CJNCZM:0W^FZC97$9*3VE[97$-S;S(2LD,J.I(85^O0G&I&,X M-2C.*E&2U3C)733\TS_87"8O#8_"X;'8.M3Q.$QF'HXK"XBE)3I5\/B*<:M& MM3FKJ5.K3G&<)+249)K<_DY_X/!?CU\B>,/$NLZ9;:Q;V&IZE90:G#: MI>PVFH7UM'.L-W.C@'^CC0`4`%`!0`4`%`!0`4`%`'^/#_P5;_X*"?MZ^!/^ M"F__``4"\%^"/VW/VN_!W@[PI^V+^T3X?\+^$_"W[27QE\/^&O#>@Z3\5/$] MCI6B:!H6D^,[32]'TC3+*&&ST_3=.M;:RLK6&*WMH8XHU4`'^GK_`,$/O'?PN_X) M"?MQ^/OAGXU\6_#KQWX:^&.AWOASQKX$\1ZQX1\6Z!>2?$CP39RW>B>(]`O- M/UC2KF2TN;FUDGL;R"5[:XG@9S%+(K`'\+'_``;'?MM_MF_&C_@L1^SY\/OC M%^UQ^TY\6/`6K>"?CW<:KX)^)?QZ^*GCOPCJ=QI?P7\::EID]_X;\4^*]5T: M\FT[4;6VO[&:XLI)+2\MX;FW:.:)'`!]V?\`!X5^UI^U1^SY^VU^S#X<^`O[ M2W[0'P2\/:Y^RNNM:SH/PC^,OQ%^&VBZMK7_``MOXA6/]L:EI?@WQ'HUC?ZH M;&TM+,W]U!+=FTM;:W\[RH(T4`_.?%'Q"\4+H]AX>^'$UCI*Z_XNU35]673+*:\NY;2P%W] MEMY+JY>&)&GE+`'],]`!0`4`%`'Y:?\`!93X[7/P)_8$^,-SI&H+I_B;XGQ: M7\'M`D\R6.X>/Q[>+I_BLV;PX9;N'P+'XGF@?S(_*D19P9#%Y4G[%X#\/PS_ M`,2\@^L4O;83)ZE3/,3%\KBY9=!U<%&:G=2A/,7A(RC9\R;CI?F7X?\`2)XC MJ\.>%'$CPU54L;G5*ED&&;E*,N3-*BHXYPYEEOUQIW7*_>N[6?\%MCJ'E ME61N!CC)Z`Y]1Z<\>HR*_P!1\+BE42C)WO?[_P`>K[:7Z7/\>,QRUQ_G:UOG?6QZ;8Z[/ITXMYI,2".VE;!)0_:;>*Y4`9KQ1>SZ;X!\5V-BSQEI+73KGQ%I>HW$67$I$4^L:>DA M$;(1-$"R%`'_`(H^EUDU2%#@W.(TE[.%?-LNK58J7NRK1PN(PU.I*SCS2AAZ MSC>2;4'9-7M_H#]!_/H5,3QYD,ZMJE3#Y-FN'HRE'WH4*F,PN*J0CSEHS)*/&7 M@L2ZK9V-N`1MF\1::-5\+>8(7AMQ!D=*G&IF>'I1SG)6US2_M3*^;$4J M4-;*6-H?6,N;=U&.,E*S<4?P:?V)-!)#:>.<9*2ERR3BXM:6UNGT:?5-:JU^A_D! M_9TJ)`L,/Q8\-V4Y MUYT18O\`A-]%UKRU59@6]S$XJGB:-',J3C&=6I.ACJ4(J*CC%%UE74%I&&,I M.(Z)6_3/$/!T>-^',J\2Z$(PSZ-:CPSXA4(1A3]MGM+#<^4\4NG#2 M,>(L!1<<;+KF^$Q5DN;WOSKOM%9=WRGWR.F2.HQ[]\_E2IXK57?H[]5KOW/P MYTJM"=E=I222ZVN]_.VA_<-_P0\^-=]\6OV#_"'AS6KV:]U[X'>*/$/P MAN);EU:@-$&=X9&/[)PAC7B\FI1 ME+FGA*D\*WUY(J-2C\E2J1A?JX/6Z9_K7]%'B^IQ3X29=AL36J5L9PMC\7P[ M6G5_B/#48T:=:R2W>NZWX>T36`#^(SXH?\`!YW^W_\` M$SQ1&_P!IW]G'5=3E\,:CJ=]X5\7>$O$MO:V/C7X9 M_$'1K;3[S7?`?C33[&\U"RM]:L++5M)U:UN+"_OM-U?0=9T?6].NYK/482`# M[EH`*`"@#_$E_P""PW_*5W_@I!_V>Y^TS_ZM[Q90!_K&_P#!$+_E$3_P3L_[ M-2^$_P#ZC\%`'Y=?\%?/^#HC]FG_`()Q_$#Q'^SC\$?`C?M5_M->%7:P\=:; M9>*(?"_PC^$VM;&\W0/&7C*ULM;U/Q!XUTLO!)JW@GPMI1BTUSM^`O&'B MB_DFM/"OACQ3;:GI&L7PLO#VG>.M1\6:QHFA:F`?I#_P<3?\H6/V_O\`LD^@ M?^K0\!4`?Y\__!J%_P`IM_V;?^Q#_:)_]45X[H`_0C_@]I_Y/S_9-_[-%7_U M'?\`!4K_`(.ZO@I^R/\`%GQG M^SU^QQ\']/\`VH?B!\/]7OO#'C?XJ>)_%ESX9^"^@>+-(O9+/6M!\-0:)97O MB+XERZ/=VUQIFIZG8ZEX2\/)?9DT76_$-O;R&0`_#FZ_X/"/^"OJ8\>C]GK] MERT^&DM_'/#+-\&/C,VBM8/<_9EL%\:/\78[2262<-:K>J@8W/R+`7'E4`?M MO_P2K_X.YOAG^U]\D^"_AK\4O`GB6_\`$_PJ MUGQKX@NUT[0/#'B_2==MH?$G@1]?U6XL-%T;7(]2\6:,^K7]NNO3>&]-\W4H M@#^S"@#^;3_@Y7U34[3]G3]GC3X6D&CWWQHU6ZU%0S>6]_I_@O48]*#H/E=A M#?ZJ8R3E1OV_>8C^E/HT2ITN)>(*LK>U634J<)67-[.IC:5ZM57?*ZE/+ZT:5[;^[5K63:W;/X][34#QAO MO#V]_7\>/S.<5_]^FOJ_P/\]LPREWG[MEKN[I^:UU?EW7W M^R^,=-U/3K/P-XIN4_XE/CSPE;ZGHUU&#Y,C>'KF;PGJU@)``&NM-O-(C^VI M\TB_;+>5QLGC+>CE.:4E+&8.G-JI@L2_;4W=R7USFQD9VO91J.K447U=.3>J M:7@9[DE><<)CJM.*IXW#*-&45H_J+^I3@WUJ0C1@YO=\R:5C[]_X),_M-6G[ M.O[:WPMUKQ!J8TWP7\0)KGX5^,;J:5([2VL?&)A@T74+QWD2.*TTWQ5#H=U= M3NQ2WM5N92"5Q7PGCCPU_KOX;9[@\+2]MF>6TX9YET5>52=?+7*=:C35G)U< M1@YXFC3A%'OBOD.8XNO]7RG-)U,@S>*5+#8]83$U9STITZ4ZFNI_?CP1Z@_B"#_`#S7^5Y_L?OJ?Q*?\%%/V;4[BPM%`"FVTG6FU72X<#` MCLU4Y*M7\J\881Y)Q)F."LXT95?K>%;TC]7Q2]K%0W]VC4E4HMO7FI2>UF_\ MN_&G@6'"OB!GV$PU)QR_,*W]M9?%0480H9E*=:K1I6LN7#XOZQ25OAC%;7/E M#P3J$^B:9\1/!DXDET#XE>$FT?4;(+O3^W-`O8O$?A'4XHV(4WMAJ=I<6,$@ M!?[-K-]"N!.Y'DX?&R4*E%3TKF0#GKU/O7?0Q>FLG\]7KNOZ[WZ'YWB\NM>\5??K\^KN^JZ]^Q M_3[_`,&\$=W:_";]I>R<$6,?Q0\(7-N.PN[GP>\5Y@8Z^3:6&>3VX'?]I\-Z MOM,%F6K:CBJ.OFZ.OX*/4_O7Z%,*M'ASCNC*_L(Y_ELZ2Z*I4RZ?M;:=8QI/ M=[KS/SQ_X/8O^4?W[+?_`&=Y9?\`JGOB=7Z0?VR?AS_P98_\I0/CG_V9#\1/ M_5V?`"@#_3ZH`*`/YQ/^"S/_``0!\+_\%;_C7X`^.'Q-_;)\9_`WPC\(/A,O M@+0/`6E_#[P_XE\,Z7)_$'B;Q9X[N-:UOQ?H7V/4?$D%_X=TC4X_LR6T5 MAX,TF0W$CO((P#D?^"(/@@/\`@H'^R7XD^*EYKNM>-/BK M\6-;\>_#&#XM^-AT.7P[X4\2>+?$*:5X0T2&'1])\*:1<7J"^_M?7 M!IL&I>(=0\T`_E6_X.H?^"D?_!.#]OWQK^SG;_L8S6/Q-^*/PM_X3V#XI?M` MZ)X(U/P=I&N^%->@\.MX9\`IJWB#2-"\0^/O[&U:QU76[2^N;"71?"W]HZA; M:#?W%UXC\00VP!^LG_!CQ?7LGP9_X*#Z;)=W3Z=:?$[X!7UK8//*UG;7NH>% M?B9!?W<%J7,,-U?0:9IL-W/&BRW,6GV4\64`?Z1'P;_:NU+]B'_@UU^$W[3_A^\L[#QC\,?^"> M/@63X>WFH0KN65XFIVT4 MX`/];JS_`."??["UA\)C\";3]C[]FR+X0-I7]BR_#X_!GP#)X=GL38OII:YM M9="=[K4&LY)(WUBXEDU=W=[A[YKEFE(!_D_?\'`7_!/GP1_P3/\`^"E_Q$^# M/P9CU#1?@UXU\,>$?CQ\&-&N;^\OK[P;X3\._ M"WB_1_#-[?7-UK`\.6.C)JVHZEJ\-YJ=X`?V@_&W]L+Q#^W1_P`&BOQ*_:"\ M<:FVL_$G4?V:=&\!?%'5YG62\UOXA?"GXU^%?AUXC\2ZB4@MH4U+QA-X;B\8 MWT-O!';6]SK\D%L##&A(!_*!_P`&H7_*;?\`9M_[$/\`:)_]45X[H`_0C_@] MI_Y/S_9-_P"S15_]7+\2J`/W*_X-.?"FM^//^"'?Q7\#>&?%UYX`\1^,_CQ^ MTMX4T'QYIUDFI:AX*UGQ%\._A_I&F>+;#3Y;FSCOK[PY>WD.L6EI+=VT=Q<6 M<<4D\2.7`!\B>&/^#4W_`()Q?L._%[X4_'3]KG_@HOX=U+X:_#OQEHOCO7/A M=\>=`^%OPO\`!_Q.LO#-X-67PQKNH:]\2'DO?#NI75G%'KVG0:;J"ZQI27VE M3PF&\F90#]V/C_\`\%X_^"'?PB^&^N>&/&'[6?[/WQ4\(_\`",264GPH^$6C M+\<]/\2:-=Q"R'A:VT#P1HFO^"W2\BN/LLVDZW?Z;I]O;/,VJ-:6,5S-&`?Y M&?Q%\5>$-;^/'CKQO\'_``]J'PX\`ZM\6_$WBKX7>%?MA.J^`_!]_P",K[5_ M!'A_^T+::0G4/"^BS:9IOVRWN9#]HL?.BG;Y7(!_O$Z,[R:1I4DC,\CZ;8N[ MNQ9W=K6)F9F8EF9B268DDDDDDF@#\:O^"^?P9N_BK_P3O\>>)M*M)KW6/@=X MJ\)?%V"&!49UT;3;Y_#7C"[?]V\IM]+\(^)M:UJY5'C00Z:T\HD$"K7ZUX*Y MTLHXZP=*I+DI9OAL3EDI-M?O:D5B,+'LY5,5AZ-*-UI*HM5=GX_XXY$\[X"Q MM2$'4JY/BL+FL8I)OV=*;H8J5WJE3PN(K59:J\:;O=I'\#=KJ'`^;&/?GCVZ M<^G)&1FO[KPV8II>\_ZT[7OIY=;VW/\`/_'91J_>(/"\VFVZ&35&KR,VS>7#V=8#B2E&RZLKR*GQ#DN8<+*FI9OAZM?/>&KJ/ M-7K4L.HYQDL9-/W\QP5&GB<%%M>TQV!AAX+FQ;;^);;5CMCE@F>-U*RQ2H3' M)%(C!XY4;ADDCVM^S7Y+B M,FLU*S3NIK=.+^RUUTOUWT733_1._P""8/[4R?M<_L;?"SXD:A=QW'C?0K%_ MAW\245U:5?&W@R.#3KV_F50NP^(-..F>)$78J*NK^7'N6/)_S1\7^$5P=QUF M^`H0Y,MQU1YME-OA6"QTYS]A'5_[IB%7PFK"7&4^-?#S)<=B MJBGFN74_[%S=\RE*>-R^$*:Q,K6UQN&=#%O1)3K3C&ZC<^%O^"U_PVL[U?@C M\28+>);_`!XI\%:G<`A9KBT3[!K>C0'Y=SI;S3:Y(#NPHN'W#[M?QMXV8*-- M9+F\5:=Z^`K2ZR5XU\,GWY7+$_\`@?EK^7?25R2GB%PSF\:W)S7XEAL:Z=2$U*SA=WU^)JRMUN[O\`X!_(M3!.A5C52]ZG)33\U?E_\!;T MM<\LU/0MJD!.BG''IQQP<`?X]Z]3#XK:\^JZOM??MIY]=[-GR6-RZW,N3UUU M]-_+YV\S^KC_`((C?"FZ\`_LAZAXQOX7AG^+OQ-\3>*[%74HQT'0H-.\$:>[ M(>OGZAXQ?\H_OV6_^SO++_P!4]\3J_0C^EC\*_P#@S#U32]&_X*:?':_U MG5-,TBR7]B7X@0FZU74;/3H&FE^-GP",<,$9IYY$AAAB\2:-)+-- M*X2.**-+TO))([*B(H+.[!5!)`H`_P`SO_@[<_X*4?'GXE_MW^,OV"?#'CSQ M;X._9U_9X\+^`;#Q9\/]%U2XT;1?B=\2_''A+1?B5J7BGQE'IL\+^*=-TC0? M%/A;0?#FBZZUWI>BW>D:MJUA907^M7=PX!]V_P#!'C_@T^_98_:-_8]^!O[6 M?[9'Q;^*OBK7/V@OA_IOQ.\-_"WX1ZWHG@KPCX0\'^+H8M1\'0ZYXFNM"U_Q M)XE\52:&;75=8^Q2^&M*T>_U2X\.'3]7?1O[=U$`^-_^#H__`()I?\$\?^"9 MOP>_8P\`?L@?"VT^'/Q#^)GCGXO^(_&5WJ/BSQCX]\;>*O"7A?PS\/\`1X+W M5O$'C/Q#KEYI.BV6N:I&VGZ+ID6F:)=ZGJ6M7=G9)+9W"J`?HK_P8[?\DF_X M*'_]E$_9V_\`4:^+5`']W%`'^,G^W[^W9_P45^&7[=7[9/P^7]M+]LKP7!X- M_:D^/?A^P\)6/[2WQJTFP\.Z7IOQ2\40:3I&FZ99>-X;+3],L=,6T@TVTLHH M[."Q2WCM46!8Q0!_L%_`CXO^`?C;\"OA5\;OA[XFT_Q#\.OB/\-O"?C[PYXF MAU&.\M+KP_KWA^RU>"ZNK^25ML]O!.4U,7(/!'C;]KS]H3Q'X6U_3;R'4=+U[1=3^*/B:X MLM;TJ_MF>WO=+U>)AJ&FW=N\D%Q8W-O+#))&ZNP!_HL_%;]F7QS\8?\`@T@\ M-?!FPTS4CXVMO^"'O"OQR\* M^/?V>)/$>L7,=GI^D>(_B#8V&I^`HYKB7*QOXC\?^%O"_@ZV=S%&EWXDA>XE MBMUFD4`_UW:`/\F[_@[0_:4\`_M#_P#!77Q3HWP]UO3?$6G_`+-WP5^'O[.? MB35](N8;W3G\=^'/$7CWX@^,M)CO+>22*:^\*:S\2Y_!^O0!O,TWQ%X?U?2+ ME8[O3YT4`_H.\'?`KQ/\`_\`@R^\?:+XPM[FQUOXB?`O4?C>FGW2HLEIX>^, M'[0^@>-?!+J$9_W>I^"-2\.:V@D(F0:IY.Z`/T(_P"#VG_D_/\`9-_[-%7_`-7+\2J`/T'_`."&W[6VN?L* M_P#!KY^V'^U;X5L;?4/&?PD^+GQYO?`<%[9KJ&FQ?$+Q1IGP=\#>`+_6=/>> MV%_H6E>,O$^AZIKMDMQ#)=Z19WL$4BRR(:`/Y-O^"?'[,'QN_P""YW_!2KPM M\*/CA^T3XJG\8?%8>,OB!\6?C;XZNKCQUXPMO"?@S2;OQ#J]IX:TO5=2LK>X MU&\D^R^'O#&A6MQ8^'O"UK?K>V^F?V)H+:3,`?Z`/P5_X-(_^"/'PC72-2\= M>"OC%\?-0T6&RN+N[^+7QAUO3-$OK[3;O[?)J>H:#\+X/ASILMO<*BVM[I5\ M;S1)M/1H;BQ;/]FTH>&?[,&GP>?-Y-IY,?FR;=[`'^[%H?_(%TC_L%Z?_ M`.DD5`&?XR\(>'/B#X0\4^`_&&E6NN^$O&OAW6O"?B?1+U/,L]7\/^(=-N=) MUC3;I/XH+[3[NXMI0"#LE;!!YK?#8FM@\3A\7AJDJ6(PM:EB*%6+M*G6HSC4 MISB^\9Q4EYHPQ6&H8W#8C!XJG&MAL51JX?$4IJ\:M&M"5.I"2ZJ<)-/U/\QO M]N']D_QO^PU^TS\0OV?O&4=[$.+J'$N38/-:$U&I4IQIXRA M'E;PN-I+_::,K:V4K3I.5N?#U*-5I.HXK^$N,>"ZW#N*_AEXT\)_$/P+K5SH' MC'P3KVF>)O#.MV/RKF$_)/;R30."DA4_9RQ.'Q MF'Q&$Q<(U\+B:,Z&(P]6//3JT:L90JTIIKWHRC)QDKIVM9W/@9Y?B,)B*6+P MLYT<3AJT,10K4Y2A5I5Z4HSI5825G&4)I2BU?L[IN_V3^UWI/@_QFGA']KWX M1Z/;:'\-OVA+W54\;>#=.54LOA%^T3I4,%_\3/`<<48"6?AWQ0;L?$7X?#"1 MOHFKZMHULFSPO/CEX9S'%9?[7AW'UYUL1EE&%3+L96DW5S'(G.5+"5*CDW*I MC,N?M&?L^7M\[:?KGAS MP[\6O#]E+*?+AU31+U?"GB9[:(@[9;VQU/PZ]QA@673T9E8H6'X[](S+X8[* MI9IP';N\JQTSPMJ-I?2$]`#$OA-X-@;^TO%&HI%>ZFT#36O MAS0;=A+KWB74%RBBST;3_.N3&TD1OKK[)I<#_;+^U1_LN&LNQG$.;8/*L$G[ M7$U$JE35QH8=6>(Q,]5I1I*4XW?[R:A33YII/AR/@W'\7Y]E^09;"U;'5U&K M7<7*&#PD&I8O&UK-?N\-24IJ+DO:U/9T(/VM2"?]J_P\\">'?AAX$\'_``Y\ M)6GV'PSX'\-Z/X7T.VR"Z:=HMC#86S3N`OG74R0B:[G8;[BYDEGD)>1B?[4P M6$HX#!X;!8:/)0PE"EAZ4>T*4%"-^\FE>3>LI-MZL_TJR?*L'D659=DV7T_9 M8'*\%AL#A:>[5'#4HTH.G4E*O\`AWX=:%/K^J:3X<3X7_$#26UF^MH" M&AL!J6I6-D9V^7[1=0Q_><5U'I'\!G_#C#_@L!_TCM_:B_\`#<:C_P#%T`'_ M``XP_P""P'_2.W]J+_PW&H__`!=`'OW[*'_!%3_@K#X._:E_9J\7>*O^"?\` M^TOHOACPM\?_`(-^(O$>LZA\.[^*PTG0M%^(OAS4M7U.^F9ML-E8:?;7%W=3 M/\D4$4DCD*I-`']/G_!S5_P;Y?M'_M:?'8_M]_L.^$K+XH^+O$?@_0/#GQ]^ M"-A>Z3HGCG5=5\%6,6B>'OB5X%;5[K3],\7RW/A&VTWP]XD\+F_M/$D!\,:- M=^'+3Q/)K-_9:(`?B)^Q'\>/^#I3]CCPG;_LF_LU?!#]LK3O`_AF;5+3PSX$ M^(7[(USXR\.>!R]]>ZAJEMX0\9?$SX=7FGZ-I$^H7US>IIUGXH?P_P#:97N- M-LT:XN'G`.M_;V_X(0_\%X_C[\+-&_;L_:YD\;?M.?M5>.O'OASX:R_L\^%) M=/\`B7\3/AY\*$\,^+=!O"VC>)+"#2H_A[\.;?4]/CU/Q MQ)XCU"ZT_5;K6X)@#]_?^#1+]D_]KW]C3PY^V[\-_P!JW]F+XN_`*3QQK?P4 M\;^`]:^(W@[4="T_Q:FDV/Q#T'Q/I>GZC);M9F\T`W7A^[>RN+R.YGAUMI[& MVEBM-1EA`/[,Z`/X2_\`@Y$_X-Q?CC^TO\;_`!-^W[^P/X7L_'_C/QUIFDR_ MM`_`&WU2RTCQ9K_BC0K*ST*'XF?#$ZU=V.A:OC MRZ]X=B\1ZUXCOM,A`/XL[GP)_P`%/O@;HOB#]FJ?PA^W?\)/"WB222'Q1\!1 MHO[0'@CPWXC?7-L$@UGX9QV^G:3KBZW\J;[K1KN/54,>QKA&0D`_77_@DQ_P M;/\`[;W[:?QC\">*_P!I_P"#7CW]F']DC0O$FFZK\2M:^+6D:M\.OB7\0/#> MF:@TNJ>"?AIX#UFWL?&L&I^)8[4Z5_PFNLZ5H_AS0-/OY?$&G7NOZA9V>@ZD M`?ZNNDZ%HV@Z%IGAG1],LM.\/:-I-EH6E:-:V\<>G6&C:=9QZ?8Z9;6H'E1V M5K8PQ6L-N%\M8$6/&T8H`_SG_P#@LG_P:9?'KPQ\5_&W[0'_``3#\+Z3\4/@ MUXRU34/%&I_LRQ:WHWAGXA_";4M2N9;W5-*^&G_"0W6D>&_&GPYMI7GF\/Z( MNM6'C3P_9O:>&;#1O%J6J:LX!^6L?C;_`(.D=(\(R_LMPV/_``5CB\+QNO@H MZ/%\/?C=)HBVR[U8)$'0`_1#_@D MI_P:9?M/?&/XJ>#?C9_P4OT#_A2'P!T35K7Q5J?P-NO$5IJ?QM^,TEO-;ZC: M>&_$W_"/7NH6OPS\&:[,[)XQOM1UM/B9+8PW^@Z=H'AK4M5MO&>@@']H?_!; MGX(>/_C%_P`$C?VQ/@5\`?AOK'CGQUXE^%7AKPS\/?AGX!T=;G5=2_LOQ[X( MN(='\.Z)9K$GE:=H^FW$L5G:HB06-DZPQ[8U2@#^*?\`X-N_^"6?_!13]E__ M`(*V_`3XQ?M!_L>-_!=WHWAO2;K7O@[XRT71H;[4 M9W\N*34]7OK+3;./#/-=742*NTNR`'VY_P`':?\`P3O_`&XOVQ_VS/V;?&O[ M+G[+GQB^.GA+PK^S$GA?Q!XC^'7A2ZU_2=)\1GXJ^/\`5FT2]NK=L0:BNF:A M87Y@<`FVO()%+!FV@'Z+_P#!#+_@F-\2O$'_``0C_:)_X)__`+;?PH^(/P%U M?X[?$[X\Z1>:+XU\.1:?XMT#2O%?A7X>1^#?B/H^CZH)+>XN/#WBG1XO$'A^ M2Z402ZOX<0G$:"0@'\\3:-:ZYH]YJ6A^*?!WQ!\*64 M%W87>I:/JUAK'AW48;O5`#]:O"9_X.Y/^"KGA.+X`>.9?BA\`/@;XZL&T#XC M_$/XE?#/P3^R;IMQX2U!/L>JQ>);W3?!WA[XR^(M/U"WBFM-4\-^!="OY=8M M;V:PUBQ.AW]T0`?B;\>?^#?#_@JM\%OCO\3OAMX#_9!^/?QR\&_#KQ]K7A[P MG\8O!?PROX/"GQ-T#1=1:/1_&N@6RZEJWV73O$%DD&H0V3ZC?361G:SN)WN( M)<`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`P;AW]Y+V)6)X&QZE4C>GB,OE'7XIO'8>"BM;N3@ZDUN^2G*^Z9Z7A)@G MA./LV4R8"NVF^&M.\"W4,JEE#:Y>0;A+# M,@_S$\9,0L95RS*X/3"QJ8RM_+[2M:%&,NS4(3FMV^9:=_T'Q4JQS7/:&$B^ M:EDN"E1DTW98W,G0Q6(A*.TG3PM#+I*6MOK%2-])I?FEHGP"\>?%;Q7!X0^' M/AB^\0ZY=/F2*W"Q6.G6S,0^HZQJ4[1V.D:='R&NKV:%'"4:5..SJ5ZTFJ="FNLZLE%V48<]2482_H,_8W_8W\)_ MLJ>%KZ4SV_B3XG>*X;7_`(3+Q>(`D4<$`$D'AKPXLD:W%IX>L[@O<2--B\UF M_/VZ_P!D<&F6&F?UWP%P)A.#,ODI3CB\WQ<(?7\:E[D5%7CA,(I)2AA*4VY) MR_>5IOVE7:G3I_U!X?\`A[E_`^#JS4H8O.L?&/\`:&/Y%%1@K2C@L&FN:G@Z M4[RU?M,14_>U=J=.E]HU]^?HA\K?M8?M!^)OV?/#OPNO/!_@?2_'WB;XJ_&K MP1\&-$TC6O$MQX4TRVU3QS%JZZ=J-YJUMHNOS1VT-]I]O!<*FG2,L-S).N]H M1#+M1IQJ.?-)Q4*E?#GXH^%/`^A_$RQ;PGXW'C_PAXE\%:YJ] MWH/VRUU:;0/#&IZ5JNFZO:BUN]*U31XVN(IDO+*>:!9"KJ4E&G&K"7-"4G%W M5I1DDG9K7=/1WZ,*5:4JDJ52')4C%3]V7/%Q;:^*R=[]&EH]+ZFWXP_:7\,? M#[X[WOPJ\=W7AOPAX1L/@?%\7KKX@^(_$EKI%K#=2^.Y?!J^'GMKY(;<[XHF MU%+I+UIF*M;_`&3`$IE4I2IJ<4Y-U.3E2;^RFG\V[%2K*%5PE:,5353G;MJY MN-M?2Y]%:1K&D^(-*T[7="U.PUG1=7LK;4M*U?2[N"_TW4M/O(EGM+ZPOK62 M6VN[2YA=)H+B"22*6-U='92#6;33::::=FGNGU3\S5--7333U33NGYW."E^- M7PB@\:+\.9OB9X'C\=O>QZ8/";^)=)77/[6EMUO(M(:Q-UYRZQ-9NEW%I+`: MC+:NERELT+JYKDGR\W++E_FL[>M^WF3[6GS[Z6O>_EN=QKVNZ M-X7T35_$GB+4[/1=`T'3;W6-:UC49TMM/TO2M.MY+N_U"^N92([>TL[6*6XN M)Y&"111O(Y"J34I-M):MNR75M_YE-J*`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`EIJMQ)::9/XKU_3-#34)X(_.N4L_P"T+F`W`M(#]HO9 M(@T=G;YN+IXH09*(PE-OEBY-;V5_ZU"=2$-9RC&_=V_KU.UL[RTU&TM=0T^Z MMKZQOK>&[LKVSGBNK2\M;B-9K>YM;F%GAN+>>)TEAFB=XY8V5T9E8$SZEIIZ MIW3ZK6_S/.](^-/PB\0>+I_`6A_$OP1JWC2VGU"UE\,Z?XETJ[UG[9I&_P#M M>RCLH;IY9[W2#')_:MG`)+G32C_;HH-C8IPFES.,DGU:=OO\_P`2%5IN7(JD M'+^7F5_/2]_4YK]I/XOW/P$^"GC?XM6FA0^)KCPA#HDJ:'<7[Z9#??VOXFT; M0&5[Z.UO7@\A-6:Z4BVE\QH!$0HJZ;-::E92'S+6ZA?YJ[,#F& M-RW$1Q6`Q5?"8B'PU:%25.5NL79VE%]8R3B^J9RXS`X/,*$L-CL-1Q5"?Q4Z MT%.-^DE?6,D]5.+4D]4TS\=/!G_!`#]E3X-_M._"C]I?]G[Q]\5OA7[TRXNKWQ'K\\$%P)+ M98Y(V\W[;$>)&=8[*<9E694,)C(XNA.A+$\DL/63E[RJRA1DJ,ZD*BA43C3I MIN%I\R9\=0\/\HP6:X7-'_B+^VC^U5-IXL?#%[\3O'7P!^#[;9$M[W0?#WCN]UO MQ=J%I$P"RZ9;RVG@[2-.O+>22*2XM-=LMZRV74OB)X MDUOQSK^JZAJ.N^)KR"-?#FGZWK^MZA-JNL7GV2&XU+4;&RDO;F:'3=.M]:VZ M3I,=CI5M.;>P@(_EK%<"Y;F6/KYAFN(Q6+JUYMRI0DL/14$_ M[6C=)/>Q]A#@/+ZU2>(S3%8C'XBO5JU\0XJ.&IU:]>I*K4ERIU:T8U*CR4HOEA&WU%X1\$>$?`6EKHO@WP[I/AS30P=[?2[2.W-Q*%"_:+R<`W%] M=,H`>[O)I[F3^.5C7U.7Y9E^54%ALNPE#!T%JX4*:AS/;FJ2^.I-]9U)2F^L MF?78'+L#EE%8?`86CA:.[A1@H\S_`)JDM9U)]YU)2D^K9U-=QVA0!\3_`+;? MP$U_]H70_@'X5TS19];\/>'?VE/AUXT^(L5GXEE\)ZC9?#[2-/\`$UIK^I:9 MK-EJNC:U;ZC:-J=FUJWAZ_AUV.5A<:>RRP[UWH5%2=23>KI3C'2]Y-JU]]-[ MW.;$TI5O8Q2;BJT93L[/D2:=FM;W:V=^O0]G^#_[-_P;^!%QX@O_`(:>$I=+ MUOQ6+&/Q+XGUWQ)XK\;^+M)+G3M.-U(;S]M#_A<%YXQY+N_M>?=VMRI+RO?YD\C>(YV MKQ]CRIZ.TN=MKOJK:^M_.[^QG\.?%_PC_9H^%WPY\>:7'HOBKPO9>(;/4M*A MOK+4H+"*Y\8>(=1TNW@O-.GN;%X$TB\L!#';3-%;1[;4+&83&CKSC4K3G'52 M:=WI=V5W\W=AAH2IT*<)*THIIKM[S:6GE8^(O'GP,_;!\>:G::+J_AG2K'0] M$_;%\%?%:5/".O\`PO\`#7PQU?X7Z1\3K'Q)%KVG^'++PW%\2=:^(EMI\4>N M>,KKQEXGLCJ6L6]Y+HZZU,UC:5O"I1A=IN[H2A=J[*,:;A&HI7MRN;GI>5Y:M)I:V/T7_:)\)Z_X\^`7QK\$ M>%;07_B?QA\*?'_ACP]8MN^%M4TS2[9KR\EAM;19KVYAC:YN9HX( M%8RRNJ*QKEIRY:D)/:,XR?7:2;.NO&4Z-6,=92IS45>UVT[:^I>^!W@*Q^&? MPD^'/@RT\-:1X4N="\$>%--UC2-%M;&WM8-:L=!L+75=\EAN@O9_MT4XFOO. MN7NY-T[7$YD,C*74;!1)=F5^BG6C&6&O*25)S;5K MO_(Y9T)R6+2C&]9PY'*WO6C%/FWT33T^>[/I:+X4^*;7]K_P;\4[+P]8V7@' M2OV8->^&E_J=G+I-F8?%%S\0O"^NZ5HO]E6\D=]+9V^D:9?RVLZ6[Z98'=;P M/%)=NKY\Z]@X7;DZRG9KIR25[]VWJOF:\DOK$)VM%4)0;O\`:E:)-X=U?2[34_A?J_P`4 M--U3P7H>KK>:@;/7M0N[==7;PY>7]IHTJRW-P&5)T_?]HVKQM'XN5OF5^;E] MYJVJ5]UJ.O&J^3V=M)WE\//RV>L'.\4^[:>C:ZF#^Q?\*OBA\*]`^.$?Q8M! M;:_X]_:(\>_$;3)V\0Z5XGN=1\-^(](\*1:5>ZAJVCZ7H-G+J:G3[BPU!4\/ MZ&OVJQDDM]-ALI;5Y*KSA-T^1Z1I1@]'%)J4FTDW)VUOJWN3AJ=2FJOM-YUI MS7O*3:DEJVDE?2VW38Q?'7PV^)_AGXU?&_XA^'OA1X<^/&B?'+X6>`_`FGZ7 MXC\1^']#MO!=WX,B\96=YX6\5P^(X)C>?"KQ2_BE=>U.3PY!KNM0ZG)KL,GA M/419"E3FJM6:A&I&K3A"TFER M\O-I*^\'S78_+GX3?L:>-O"GB?P/X<\<:)XZ\3KX"^/GC#XTV_Q7@^+/A?1 MO!%Y=:OXK\3>)=,\46OA2QT&Z^)%[X[UC3M;MO#?C/PQK)MO"]^9-4HOE2YW*S2<6N32]]7?[N_:B^&.N_&?\`9W^,OPK\,7-A:>)/'7P_ M\0Z!H,VJ/)%IHU>[LG.GQWTT22206L]TD4$]RD4K6\&>#?!'QD\0_M+_``;^+?BOX7)\ M/_"OA']G3Q[\.-8AN_&_ASQ-K=KXLUCQ/\/]0M+2XM]!EDLVTN:T\.ZA/I>J M:==7SW:-)_;-EH%PEI:7&CE3C1G3C/GE*I"?PM*T8S776_O:].U]S*,*CKTZ MDHJ,8T9P?O*3YI2@^G2T=[W=]E;7T3]KSX<>./B1\./"4'P_T:'Q'K_@GXT_ M!WXGR^'FU:QT6[US1_A]XYTOQ'K&F:3J.JR6^DQ:Q<6-I+_9RZK=V5A+<*J7 M%W`"K5%&48S?,VE*%2%UK\<7'6VMM=;:]B\1"4X)17,XU*<[7M=0FI.WGII? MJ?3MA//=6-E=7-C/IESG4_"M_X+\#:-:ZC(EG<3O8R2:AH>HQ?8KU8+Q(XHY7A5)HR=*DHR5. MU_=IJ,O\7--NWR:U[W,*,)0GB&U95*SG'6]TX05W\T_DUSP/JD7BVY\32ZMI4GBJ2UT6[\*^.XK MRST_QSY%Z-TO9OGTM9VZPU<=+>\] M5NYG":K^U4/:)T_9VYDG#WG)MU/PI\+_``;X;N?# M7@?P9J^C^%=.L)O"7@"*YB^'WAG4(K-0VA^%TEM-.N6\.Z7.?L=E(=/TYYK6 M$3)867F+:Q93:E.3O*2N[WW^9M!.,(QM&+44K1OR)]HW2?*NFB MTZ'YG^$?@9^UUKOC?]EC4?B5X9T_1]-^#OQM\4>+_'MAX;U_X6Z7\+K6TO?# M?CO3-&UGX2^"O"?AK2_%"Z+(=?@M[Z;QOKTWBM;S4[JXFT2[6YOM0L>IU*2C M7Y9.]2"C%R4Y2>L;J4F^6^CM9:))79Q1I8F4J#FE^[JN4K."A;EG%>SA&/,M M)?:DW>Y]K_ME_#GQ?\6_V:OB;\//`6F)K/BWQ';>&8](TV6^LM-CN7T[QIX< MUB[#7VHSVUE`([#3[N8&>9`YC$2;I'16YZ4E"I&4KV5[VWUBU^;.K$1E.C., M5>3Y;+O:<6_P3/IQ?NKG(.T<'KT[X)Y_$_6LS8=0`4`%`'&_$67Q=#X!\:R> M`-.L]7\=?\(MKR^#--U*[CL-,O/%4FF7,>@0ZI?2AEL]+.JO:G4[H1SRP6(N M)8;:YF5+>7?"J@\3AUBIRIX;VU+ZQ.,7.<:/.O:N$%9RFH&A&IB%2J>PA.2A"=;E?LU.;3Y8.=N:5I-1NTI/1^;?LN_L_>$_P!E M?]G[X4_L_P#@IWNM%^&?A*PT.76+B)8;[Q/K\ADU'Q7XQU5$9U_MCQAXGO=7 M\3:L0[K_`&AJMP$;8%`[:8S,\0E&>*J\T*47>&'H0BJ6&PU/1?N\- MAX4Z$-$W&";]YMOBR7*Z.2Y9A,MH-SCAJ;]I5E\>(Q%24JV*Q-3?]YB<14JU MYZV4JC2T2/>Z\L]0*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H =`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`_]D_ ` end